Angiotensin II promotes steroid-induced avascular necrosis of the femoral head in mice

doi:10.3969/j.issn.2095-4344.1186

Abstract

Abstract:

BACKGROUND: There are many studies on the pathogenesis of steroid-induced avascular necrosis of the femoral head, but the relevant mechanisms remain unclear. Local obstruction of blood flow to the femoral head is an important cause of avascular necrosis of the femoral head.
OBJECTIVE: To investigate the effect of angiotensin II on avascular necrosis of the femoral head.
METHODS: Male Balb/c mice were randomly divided into three groups. In the dexamethasone plus angiotensin II group, 2 mg/L dexamethasone was added in drinking water, subcutaneous implantatian with osmotic pump capsules began on the first day, followed by pumping with 0.28 mg/(kg?d) angiotensin II for 4 weeks. Dexamethasone group dosage and usage were the same as dexamethasone plus angiotensin II group. Control group had normal feed. All mice were fed for 6 weeks.
RESULTS AND CONCLUSION: (1) General condition and pathological changes showed that compared with the dexamethasone and control groups, the body mass increase was significantly decreased, and the serum total cholesterol, total triglyceride, empty lacunae rate and bone volume/tissue volume were significantly increased in the dexamethasone plus angiotensin II group (P < 0.05), and the degree of osteonecrosis was more obvious. (2) Immunohistochemical results showed that the osteoprotegerin protein expression level in the dexamethasone plus angiotensin II group was significantly higher than that in the other two groups (P < 0.05), indicating that the osteoclast was more active. (3) In summary, angiotensin II can obviously promote steroid-induced avascular necrosis of the femoral head in mice.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

Key words: angiotensin II, steroid, avascular necrosis of the femoral head, mice, cholesterol, low density lipoprotein, high density lipoprotein, total triglyceride, immunohistochemical staining

CLC Number:

Liu Baoyi1, Li Minde1, Yang Fan2, Li Shaopeng1, Chen Haojie1, Xiao Peng1. Angiotensin II promotes steroid-induced avascular necrosis of the femoral head in mice[J]. Chinese Journal of Tissue Engineering Research, 2019, 23(19): 3044-3049.

Figures/Tables 2

References

[1] 王傲,王金成.激素性股骨头坏死发病机制的研究进展[J].中国骨与关节损伤杂志,2016,31(4):445-446.

[2] Dinh QN, Drummond GR, Kemp-Harper BK, et al. Pressor response to angiotensin II is enhanced in aged mice and associated with inflammation, vasoconstriction and oxidative stress. Aging. 2017;9(6):1595-1606.

[3] Yang L, Boyd K, Kaste SC, et al. A mouse model for glucocorticoid-induced osteonecrosis: effect of a steroid holiday. J Orthop Res. 2009;27(2):169-175.

[4] Qin L, Zhang G, Sheng H, et al. Multiple bioimaging modalities in evaluation of an experimental osteonecrosis induced by a combination of lipopolysaccharide and methylprednisolone. Bone. 2006;39(4):863-871.

[5] Okazaki S, Nishitani Y, Nagoya S, et al. Femoral head osteonecrosis can be caused by disruption of the systemic immune response via the toll-like receptor 4 signalling pathway. Rheumatology (Oxford). 2009;48(3):227-232.

[6] Yamamoto T, Hirano K, Tsutsui H, et al. Corticosteroid enhances the experimental induction of osteonecrosis in rabbits with Shwartzman reaction. Clin Orthop Relat Res. 1995;(316):235-243.

[7] Yamamoto T, Irisa T, Sugioka Y, et al. Effects of pulse methylprednisolone on bone and marrow tissues: Corticosteroid-induced osteonecrosis in rabbits. Arthritis Rheum. 1997;40(11):2055-2064, .

[8] Blair JM, Zheng Y, Dunstan CR. RANK ligand. Int J Biochem Cell Biol. 2007;39(6):1077-1081.

[9] Yamada Y, Ando F, Niino N: et al. Association of polymorphisms of the osteoprotegerin gene with bone mineral density in Japanese women but not men. Mol Genet Metab. 2003;80(3):344-349.

[10] Gori F, Hofbauer LC, Dunstan CR, et al. The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology. 2000;141(12): 4768-4776.

[11] Zeng X, Zhan K, Zhang L, et al. The impact of high total cholesterol and high low-density lipoprotein on avascular necrosis of the femoral head in low-energy femoral neck fractures. J Orthop Surg Res. 2017;12(1):30.

[12] Mukisi M, Bashoun K, Burny F. Sickle-cell hip necrosis and intraosseous pressure. Orthop Traumatol Surg Res. 2009; 95(2):134-138.

[13] Wang G, Zhang CQ, Sun Y, et al. Changes in femoral head blood supply and vascular endothelial growth factor in rabbits with steroid-induced osteonecrosis. J Int Med Res. 2010; 38(3): 1060-1069.

[14] Zheng L, Wang W, Ni J, et al. The association of e NOS gene polymorphism with avascular necrosis of femoral head. PLoS One. 2014;9(2):e87583.

[15] Tian L, Wen Q, Dang X, et al. Immune response associated with Toll-like receptor 4 signaling pathway leads to steroid- induced femoral head osteonecrosis. BMC Musculoskelet Disord. 2014;15:18.

[16] Assouline-Dayan Y, Chang C, Greenspan A, et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum. 2002;32(2):94-124.

[17] Mont MA, Jones LC, Hungerford DS. Nontraumaticosteonecrosis of the femoral head: ten years later. J Bone Joint Surg Am. 2006;88(5):1117-1132.

[18] Lieberman JR, Berry DJ, Mont MA, et al. Osteonecrosis of the hip:management in the 21st century. Instr Course Lect. 2003; 52:337-355.

[19] Law RK, Lee EW, Poon PY, et al. The functional capacity of healthcare workers with history of severe acute respiratory distress syndrome (SARS) complicated with avascular necrosis-case report. Work. 2008;30(1):17-26.

[20] Chan MH, Chan PK, Griffith JF, et al. Steroid-induced osteonecrosis in severe acute respiratory syndrome: a retrospective analysis of biochemicalmarkers of bone metabolism and corticosteroid therapy. Pathology. 2006; 38(3):229-235.

[21] Kerachian MA, Seguin C, Harvey EJ. Glucocorticoids in osteonecrosis of the femoral head: a new understanding of the mechanisms of action. J Steroid Biochem Mol Biol. 2009;114(3-5):121-128.

[22] Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012;41(2):183-190.

[23] Kerachian MA, Harvey EJ, Cournoyer D, et al. Avascular necrosis of the femoral head: vascular hypotheses. Endothelium. 2006;13:237-244.

[24] Ong SL, Whitworth JA. How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids. Endocrinol Metab Clin North Am. 2011;40(2):393-407.

[25] Kerachian MA, Harvey EJ, Cournoyer D, et al. Avascular necrosis of the femoral head: vascular hypotheses. Endothelium. 2006;13(4):237-244.

[26] Touyz RM, Montezano AC. Angiotensin-(1-7) and vascular function: the clinical context. Hypertension. 2018;71(1):68-69.

[27] Hofbauer LC, Neubauer A, Heufelder AE. Receptor activator of nuclear factor-kappa B ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer. 2001;92(3):460-470.

[28] Singh PP, van der Kraan AG, Xu J, et al. Membrane-bound receptor activator of NFκB ligand (RANKL) activity displayed by osteoblasts is differentially regulated by osteolytic factors. Biochem Biophys Res Commun. 2012;422(1):48-53.

[29] Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008; 473(2):139-146.

[30] Theoleyre S, Wittrant Y, Tat SK, et al. The molecular triad OPG/RANK/RANKL: Involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004;15(6):457-475.